Biologic Therapies Summit X and Vasculitis online series

Infections, COVID-19, Co-Morbidities with IMIDS

Release date: July 13, 2023
Expiration date: July 12, 2025

Estimated Time of Completion: 2 hours

Session Agenda:
Immunizations in the immunocompromised
Kevin Winthrop, MD, MPH, Oregon Health & Science University

Optimal management of COVID-19 in the immunocompromised
Cassandra Calabrese, DO, Cleveland Clinic

Long COVID
Leonard Calabrese, DO, Cleveland Clinic

Current status of COVID vaccinology in the compromised host
Alfred Kim, MD, PhD, St. Louis

Description

Watch Biologic Therapies Summit X and Vasculitis Online Series, on-demand, complimentary webcasts that brings together world leaders in immune-based therapies to address cutting-edge topics in immunology and rheumatology. Education focuses on vasculitis, including key issues in the differential diagnosis of vasculitis, CNS vasculitis, ANCA-associated vasculitis, and organ-specific issues in vasculitis. In addition, the online series features talks on CAR T-cell therapy, irAEs, precision medicine and the next generation of JAK inhibitors for IMIDs, and advances in complement biology and therapy. A deep dive into rheumatoid arthritis, AS, PsA and SpA, infections, COVID-19, co-morbidities with IMIDs, including ILD and cardiovascular risk in immune-mediated diseases, and lupus. Lastly, the CE-certified webcasts address pain management and the exploration of the social and scientific fundamentals of pain.

Learning Objectives

Summarize evidence on COVID-19 and vaccinations and their effects on patients with immune-mediated inflammatory diseases, and describe the implications for clinical practice.
Critically appraise how Long COVID presents in patients with immune-mediated inflammatory diseases.
Evaluate comorbidities such as cardiovascular risk and complications associated with immune-mediated diseases.
Discuss how the pandemic may potentially end and what it means for us and our patients.
Identify the immunocompromised and what their risks and complications are.
Develop a strategy to prevent and care for such patients.
Define Long COVID and its epidemiology, endotypes, and its immunopategenesis.
Highlight the controversies of and what is known regarding therapy of Long COVID.

Target Audience

The online series is directed to rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, pharmacists, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

Accreditation

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians / American Medical Association (AMA)
Cleveland Clinic Foundation Center for Continuing Education designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Nurses / American Nurses Credentialing Center (ANCC)
Cleveland Clinic Center for Continuing Education designates this enduring activity for a maximum of 2.0 ANCC contact hours.

Physician Assistants / American Academy of PAs (AAPA)
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Credit
This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Certificate of Participation
A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

Activity Director and Faculty

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair of Rheumatology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Carol Langford, MD, MHS
Director, Center for Vasculitis Care and Research
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Planning Committee

Cassandra Calabrese, DO
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Elizabeth (Betsy) Kirchner, DNP
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Amanda Mixon, PA-C
UCHealth Rheumatology Clinic - Harmony Campus
University of Colorado Health
Fort Collins, CO

Faculty

Alfred Kim, MD, PhD
Division of Rheumatology
Washington University
St. Louis, MO

Kevin Winthrop, MD, MPH
Professor of Infectious Diseases, Ophthalmology,
Professor of Public Health and Preventive Medicine (joint appointment),
Division of Infectious Diseases
Oregon Health & Science University
Portland, OR

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

Cassandra Calabrese, DO
Astra Zeneca, Lilly	Consulting
Sanofi-Regeneron	Consulting Teaching and Speaking

Leonard Calabrese, DO
Astra Zeneca, BMS	Teaching and Speaking
Novartis, Regeneron, Sanofi Aventis	Consulting
Genentech/Roche	Consulting Advisor or review panel participant Teaching and Speaking
Abbvie Pharmaceuticals, Janssen, UCB	Consulting Teaching and Speaking

M. Elaine Husni, MD, MPH
Abbvie Pharmaceuticals, Amgen, Bristol-Myers Squibb Co, Genzyme/Sanofi, Janssen, Lilly, Regeneron	Consulting Advisor or review panel participant
Celgene Corporation, Pfizer, Inc.	Advisor or review panel participant
Genenetch, UCB, Inc.	Consulting
Novartis Pharmaceuticals	Consulting Advisor or review panel participant Teaching and Speaking
WebMD	Consulting Teaching and Speaking

Alfred Hyoungju Kim, MD
Aurinia Pharmaceuticals, Exagen Diagnostics, GlaxoSmithKline	Consulting Teaching and Speaking
Alexion, ANI Pharmaceuticals, Astrazeneca Pharmaceuticals, Pfizer, Inc.	Consulting
Foghorn Therapeutics	Research: PI on investigator-initiated study
UpToDate, Inc.	Independent Contractor: Co-author on a section on COVID and immunosuppression
Kypha	Consulting Intellectual property rights (Royalties or patent sales)

Elizabeth Kirchner, DNP
Janssen Pharmaceuticals, Inc.	Consulting
RhAPP	Teaching and Speaking
Boehringer Ingelheim, Horizon Pharma, UCB	Advisor or review panel participant

Carol Langford, MD
Astrazeneca Pharmaceuticals	Other activities from which remuneration is received or expected: Non-paid consultant for research Clinical trial funding support - this has ended
Bristol-Myers Squibb Co.	Other activities from which remuneration is received or expected: Clinical trial funding support Non- paid consultant for research
Chemocentryx, GlaxoSmithKline	Other activities from which remuneration is received or expected: Clinical trial funding support
Abbvie Pharmaceuticals	Other activities from which remuneration is received or expected: Non- paid consultant for research

Amanda Mixon, PA-C
Abbvie Pharmaceuticals	Consulting Advisor or review panel participant Teaching and Speaking
Eli Lilly, Janssen Pharmaceuticals, Inc	Advisor or review panel participant Teaching and Speaking
Amgen	Teaching and Speaking
Astrazeneca Pharmaceuticals, RhAPP, Sanofi	Advisor or review panel participant
UCB, Inc.	Consulting

Kevin Winthrop, MD
Abbvie Pharmaceuticals, Astra Zeneca, Galapagos, Genentech/Roche, Gilead Sciences, Inc, GSK, Lilly, Novartis, Regeneron, Sanofi, UCB	Consulting
Bristol-Myers Squibb Co., Pfizer	Consulting Other activities from which remuneration is received or expected: research grant
Abbott Laboratories, Cellestis	Advisor or review panel participant
Oxford Immunotech	Other activities from which remuneration is received or expected: research grant

Acknowledgment

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this live activity from:

AbbVie, Inc.
Amgen, Inc.
AstraZeneca Pharmaceuticals
Bristol Myers Squibb
Genentech
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation
Pfizer, Inc.

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this enduring activity from:

AbbVie, Inc.
Amgen, Inc.
AstraZeneca Pharmaceuticals
Bristol Myers Squibb
Genentech
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s R.J Fasenmyer Center for Clinical Immunology.

Home

Live Events

Text-Based CME

Webcasts

Journal CME

Self-Study CME